INVO Fertility to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026
Rhea-AI Summary
INVO Fertility (Nasdaq: IVF) will participate in a webcast fireside chat at the Lytham Partners 2026 Investor Healthcare Summit on Thursday, January 15, 2026. The live webcast begins at 3:00 p.m. ET and will be available at the conference page https://lythampartners.com/hc2026/ivf. A replay will be accessible at the same link after the event. The company focuses on establishing, acquiring, and operating fertility clinics and related technologies.
Positive
- None.
Negative
- None.
News Market Reaction – IVF
On the day this news was published, IVF gained 1.01%, reflecting a mild positive market reaction. This price movement added approximately $21K to the company's valuation, bringing the market cap to $2M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
IVF slipped 1.14% while peers were mixed: VERO +1.33%, TIVC +2.99%, NAOV -1.95%, NUWE +1%, RMED flat. Moves do not indicate a unified sector trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 30 | Leadership realignment | Positive | +10.0% | Executive shifts to support clinic acquisition-focused growth strategy. |
| Dec 17 | Acquisition agreement | Positive | -9.8% | Definitive deal to acquire Indiana fertility clinic Family Beginnings. |
| Dec 02 | Private placement | Negative | -11.8% | At-the-market private placement with shares and warrants for <b>$4.0M</b>. |
| Nov 28 | Acquisition intent | Positive | +11.0% | Initial announcement of intent to acquire Family Beginnings clinic. |
| Nov 25 | Reverse stock split | Negative | -20.2% | Announcement of <b>1-for-8</b> reverse stock split effective Nov 28, 2025. |
News with clearly positive strategic tone has sometimes seen negative or muted reactions, while financing and reverse split headlines have generally aligned with negative price moves.
Over the past few months, INVO Fertility has focused on reshaping its capital structure and clinic footprint. A 1-for-8 reverse split on Nov 28, 2025 preceded acquisition plans for the Family Beginnings clinic, first announced on Nov 28, 2025 and formalized with a definitive agreement on Dec 17, 2025. The company also priced a $4.0 million private placement on Dec 2, 2025 and realigned leadership on Dec 30, 2025 to support its clinic-acquisition growth strategy. Today’s conference participation fits within this ongoing investor and strategic communication effort.
Market Pulse Summary
This announcement highlights INVO Fertility’s plan to engage investors through a webcast fireside chat on January 15, 2026 at 3:00 p.m. ET during the Lytham Partners Healthcare Summit. It follows recent actions including a reverse split, clinic acquisition steps, and capital raises. Investors tracking the story may focus on management’s commentary around clinic growth, financing strategy, and operational progress. Future filings and transaction updates will be key to understanding how the communication translates into execution.
AI-generated analysis. Not financial advice.
SARASOTA, Fla., Jan. 13, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO” or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced that it will participate in a webcast fireside chat at the Lytham Partners 2026 Investor Healthcare Summit, taking place virtually on Thursday, January 15, 2026.
The webcast will take place at 3:00 p.m. ET on Thursday, January 15, 2026. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/hc2026/ or directly at https://lythampartners.com/hc2026/ivf. A replay will also be available through the same links.
About INVO Fertility
We are a healthcare services fertility company dedicated to expanding access to assisted reproductive technology (“ART”) care to patients in need. Our principal commercial strategy is focused on building, acquiring, and operating fertility clinics, including “INVO Centers” dedicated primarily to offering the intravaginal culture (“IVC”) procedure enabled by our INVOcell® medical device (“INVOcell”) and US-based, profitable in vitro fertilization (“IVF”) clinics. We have two operational INVO Centers in the United States and one IVF clinic. We also continue to engage in the sale and distribution of INVOcell to third-party owned and operated fertility clinics. INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman's body. The IVC procedure provides patients with a more connected, intimate, and affordable experience in comparison to other ART treatments. We believe the IVC procedure can deliver comparable results at a fraction of the cost of traditional IVF and is a significantly more effective treatment than intrauterine insemination. For more information, please visit invofertility.com.
For more information, please contact:
INVO Fertility, Inc.
Steve Shum, CEO
978-878-9505
sshum@invofertility.com
Investor Contact
Lytham Partners, LLC
Robert Blum
602-889-9700
INVO@lythampartners.com
FAQ
When will INVO Fertility (IVF) present at the Lytham Partners 2026 Investor Healthcare Summit?
How can investors access the INVO (IVF) webcast on January 15, 2026?
Will a replay of the INVO Fertility (IVF) presentation be available after January 15, 2026?
What topics will INVO Fertility (IVF) likely cover in the Lytham Partners fireside chat?
Is the INVO Fertility (IVF) presentation at Lytham Partners 2026 free to view?
